Kuriakose Emil 4
4 · Terns Pharmaceuticals, Inc. · Filed Apr 2, 2026
Research Summary
AI-generated summary of this filing
Terns (TERN) CMO Kuriakose Emil Sells 942 Shares
What Happened Kuriakose Emil, Chief Medical Officer of Terns Pharmaceuticals (TERN), sold 942 shares on April 1, 2026, for a total of approximately $49,693. The sale was reported on a Form 4 filed April 2, 2026 and is noted as an open-market/private sale to satisfy tax withholding associated with the vesting of a previously granted restricted stock unit (RSU) award.
Key Details
- Transaction date: 2026-04-01; Form 4 filed: 2026-04-02 (appears timely).
- Shares sold: 942 at a weighted-average price of $52.75 per share (range $52.735–$52.77).
- Proceeds: ~$49,693.
- Transaction code: S (Sale). Footnote F1: sale made to satisfy taxes on RSU vesting (not a discretionary trade). Footnote F2: sale price is a weighted average across the indicated range; detailed split available on request.
- Shares owned after the transaction: not specified in the provided summary—see the full Form 4 for holdings details.
Context Tax-withholding sales following RSU vesting are common and typically procedural (used to cover tax obligations) rather than a direct signal of the insider’s view on the company. This was not an option exercise or a gift; it was a sale tied to tax withholding.
Insider Transaction Report
Form 4
Kuriakose Emil
Chief Medical Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-04-01$52.75/sh−942$49,693→ 105,673 total
Footnotes (2)
- [F1]Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person.
- [F2]This sale price represents the weighted average sale price of the shares sold ranging from $52.735 to $52.77 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Signature
/s/ David Strauss, as Attorney-in-Fact for Emil Kuriakose|2026-04-02